Antidepressants in bipolar depression
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
If I had to decide on which is currently the most controversial issue in the area of bipolar disorder research and treatment I would not hesitate to point at the use of antidepressants in bipolar depression. As Licht et al. emphasize in their excellent review published in this issue of the Acta Psychiatrica Scandinavica (1), the main source of controversy is the lack of high quality data. Indeed, antidepressants have been poorly assessed for their use in bipolar depression. The main reason for this is that, like it or not, most of the evidence base in clinical psychopharmacology comes from industry-sponsored trials (2), and the industry could never find any advantage in pursuing a specific indication for bipolar depression for any antidepressant drug, as a general indication for major depression would be enough for them to promote the drug for all types of major depression; moreover, bipolar depression was traditionally seen as a ‘minor piece of the pie’. On the other hand, the companies promoting drugs labeled as ‘mood stabilizers’ or ‘antipsychotics’ are indeed interested in pursuing an indication that would expand their current marketing scope, and the assumption, true or false, that antidepressants cause mania concurs with their strategy. Regrettably, there have been also few attempts from independent researchers to conduct good quality trials in this area. As a consequence of all this, we are still uncertain on whether antidepressants are effective (3), ineffective (4), safe (5) or unsafe (6) in bipolar depression, and they might end up being the four things at the same time, depending on their class, particular pharmacodynamics, and concomitant therapy (7, 8). Hence, the lack of extensive and robust data on this topic leaves us with the uncertainty of whether we are actually helping or hurting a patient with bipolar depression when the decision to prescribe an antidepressant is made. If I can give my opinion, I have the feeling that the main driver of antidepressant use in bipolar depression is the unmet need of treating effectively bipolar disorder, and particularly depressive symptoms, which are the most prevalent, enduring, and disabling (9, 10). Clinicians who struggle on a daily basis with bipolar patients with depressive symptoms know how difficult it is to achieve full remission and to find the balance between efficacy and tolerability; the patients, on the other hand, demand solutions to their suffering and may often be the first to suggest trying an antidepressant. Another issue is how many bipolar depressions are being treated with antidepressants in primary care with the assumption that they are just unipolar depressions. As a matter of fact, antidepressants are the most commonly prescribed drugs in bipolar disorder (11), way ahead of mood stabilizers and antipsychotics, despite the evidence base is much better for the latter. Of particular concern, most patients are treated with antidepressant monotherapy, which does not provide any protection against manic episodes and might cause manic switch, mixed outbursts, cycle acceleration, and even increased suicidality in particular age ranges. Thus, although I concur with authors like Möller and Grunze (12), Parker et al. (13), and Licht et al. (1) that there may be a place for antidepressants as adjuncts in the treatment of bipolar depression, I think that our educational efforts should go in the direction of promoting better diagnosis of bipolar spectrum disorders, and rational use of pharmacotherapy, which implies a cautious use of antidepressants as adjuncts and an emphasis on long-term therapies and psychoeducation (14). In the research arena, we need adequately powered clinical trials that address the efficacy and safety of antidepressants. A recent example is the trial called EMBOLDEN II (15), in which two doses of quetiapine and paroxetine monotherapy were compared to placebo. Paroxetine did not separate from placebo in antidepressant efficacy, but the switch rate was also similar to that of placebo; unfortunately, the paroxetine dose was only 20 mg/day, which is in the range of its anxiolytic effects but could be argued as too low for bipolar depression. Moreover, we tend to use the generic name ‘antidepressants’ as if they were a class, but these drugs may have significantly different liabilities in efficacy and safety in bipolar depression. Clearly, further research is needed in this area and if the industry is not going to promote it, perhaps the governments, regulatory bodies, scientific societies, and research networks should provide the funding to conduct the studies that would provide answers to an issue which, in my opinion, is a huge safety concern in current clinical care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064135 · Cited by 937 · cited 1×
“As a consequence of all this, we are still uncertain on whether antidepressants are effective (3), ineffective (4), safe (5) or unsafe (6) in bipolar depression, and they might end up being the four things at the same time, depending on their class, particular pharmacodynamics, and concomitant therapy (7, 8).”
BackgroundThree times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder 1
Kupka, R. W., Altshuler, L. L., Nolen, W. A., Suppes, T., Luckenbaugh, D. A., Leverich, G. S., Frye, M. A., Keck, P. E., McElroy, S. L., Grunze, H., et al. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00467.x · Cited by 397 · cited 1×
“If I can give my opinion, I have the feeling that the main driver of antidepressant use in bipolar depression is the unmet need of treating effectively bipolar disorder, and particularly depressive symptoms, which are the most prevalent, enduring, and disabling (9, 10).”
Background
Cited by
Pacchiarotti, I., Bond, D. J., Baldessarini, R. J., Nolen, W. A., Grunze, H., Licht, R. W., Post, R. M., Berk, M., Goodwin, G. M., Sachs, G. S., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13020185 · Cited by 770
Self-citationGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399
Self-citationAmsterdam, J. D., Lorenzo-Luaces, L., Soeller, I., Li, S. Q., Mao, J. J., & DeRubeis, R. J. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.05.070 · Cited by 57
Metadata
- Authors
- Vieta, E.
- Venue
- Acta Psychiatrica Scandinavica
- Publisher
- Wiley
- Published
- 2008-10-09
- Volume
- 118
- Issue
- 5
- Pages
- 335-336
- ISSN
- 0001-690X (ISSN-L)
- 1600-0447
- OpenAlex
- W1968266057
- Cited by
- 43
- References
- 2
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antidepressants in bipolar depression. https://app.cochat.ai/papers/10.1111/j.1600-0447.2008.01233.x
- The paper
- Vieta, E. (2008). Antidepressants in bipolar depression. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.2008.01233.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.